Evidence map›Paper›PMID 27803184›Full record

ArticlemBio2016

A Class 1 Histone Deacetylase with Potential as an Antifungal Target.

Ingo Bauer, Divyavaradhi Varadarajan, Angelo Pidroni, Silke Gross, Stefan Vergeiner, Birgit Faber, Martin Hermann, Martin Tribus, Gerald Brosch, Stefan Graessle

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. HISTONE DEACETYLASE-1 is required for epigenome stability inProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Therapeutic Approaches for CombatingCurrent drug targets · 2022
    Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Lysine acetylation as drug target in fungi: an underexplored potential in Aspergillus spp.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ingo BauerDivision of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Divyavaradhi VaradarajanDivision of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Angelo PidroniDivision of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Silke GrossDivision of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Stefan VergeinerDivision of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Birgit FaberDivision of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Martin HermannDepartment of Anesthesiology and Intensive Care Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Martin TribusDivision of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Gerald BroschDivision of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Stefan GraessleDivision of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria stefan.graessle@i-med.ac.at.
Innsbruck Medical University · ATUniversität Innsbruck · AT

Funding

Austrian Science Fund FWF P 24803
6 · The paper itself

Abstract

Histone deacetylases (HDACs) remove acetyl moieties from lysine residues at histone tails and nuclear regulatory proteins and thus significantly impact chromatin remodeling and transcriptional regulation in eukaryotes. In recent years, HDACs of filamentous fungi were found to be decisive regulators of genes involved in pathogenicity and the production of important fungal metabolites such as antibiotics and toxins. Here we present proof that one of these enzymes, the class 1 type HDAC RpdA, is of vital importance for the opportunistic human pathogen Aspergillus fumigatus Recombinant expression of inactivated RpdA shows that loss of catalytic activity is responsible for the lethal phenotype of Aspergillus RpdA null mutants. Furthermore, we demonstrate that a fungus-specific C-terminal region of only a few acidic amino acids is required for both the nuclear localization and catalytic activity of the enzyme in the model organism Aspergillus nidulans Since strains with single or multiple deletions of other classical HDACs revealed no or only moderate growth deficiencies, it is highly probable that the significant delay of germination and the growth defects observed in strains growing under the HDAC inhibitor trichostatin A are caused primarily by inhibition of catalytic RpdA activity. Indeed, even at low nanomolar concentrations of the inhibitor, the catalytic activity of purified RpdA is considerably diminished. Considering these results, RpdA with its fungus-specific motif represents a promising target for novel HDAC inhibitors that, in addition to their increasing impact as anticancer drugs, might gain in importance as antifungals against life-threatening invasive infections, apart from or in combination with classical antifungal therapy regimes. IMPORTANCE: This paper reports on the fungal histone deacetylase RpdA and its importance for the viability of the fungal pathogen Aspergillus fumigatus and other filamentous fungi, a finding that is without precedent in other eukaryotic pathogens. Our data clearly indicate that loss of RpdA activity, as well as depletion of the enzyme in the nucleus, results in lethality of the corresponding Aspergillus mutants. Interestingly, both catalytic activity and proper cellular localization depend on the presence of an acidic motif within the C terminus of RpdA-type enzymes of filamentous fungi that is missing from the homologous proteins of yeasts and higher eukaryotes. The pivotal role, together with the fungus-specific features, turns RpdA into a promising antifungal target of histone deacetylase inhibitors, a class of molecules that is successfully used for the treatment of certain types of cancer. Indeed, some of these inhibitors significantly delay the germination and growth of different filamentous fungi via inhibition of RpdA. Upcoming analyses of clinically approved and novel inhibitors will elucidate their therapeutic potential as new agents for the therapy of invasive fungal infections-an interesting aspect in light of the rising resistance of fungal pathogens to conventional therapies.

Indexed as

Gene Expression Regulation, FungalGenes, EssentialMicrobial ViabilityAntifungal AgentsAspergillus fumigatusAspergillus nidulansChromatinHistone Deacetylase InhibitorsHistone DeacetylasesHydroxamic AcidsAntifungal AgentsChromatinHistone Deacetylase InhibitorsHistone DeacetylasesHydroxamic Acidstrichostatin A

Identifiers

PMID27803184
PMCPMC5090035
OpenAlexW2547564730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.